Trial Profile
A Phase I,Open,Mono-center and Dose Escalation Study Investigating Tolerance and Pharmacokinetics of Single and Multiple Doses of Anti-PD-1 Monoclonal Antibody in Patients With Triple-negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Toripalimab (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Shanghai Junshi Biosciences
- 22 Oct 2019 Status changed from active, no longer recruiting to completed.
- 07 Mar 2019 Planned End Date changed from 1 May 2019 to 1 Dec 2019.
- 26 Jun 2018 Planned primary completion date changed from 1 May 2018 to 1 Dec 2018.